相似文献
1
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.
Clin Pharmacol Ther. 2019 Oct;106(4):726-733. doi: 10.1002/cpt.1477. Epub 2019 Jul 5.
2
Meta-analysis of the associations of CYP2B6-516G>T polymorphisms with efavirenz-induced central nervous system side effects and virological outcome in HIV-infected adults.
Pharmacogenomics J. 2020 Apr;20(2):246-259. doi: 10.1038/s41397-019-0112-2. Epub 2019 Oct 21.
3
Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.
J Antimicrob Chemother. 2014 Aug;69(8):2175-82. doi: 10.1093/jac/dku110. Epub 2014 Apr 11.
4
Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand.
Clin Ther. 2020 Jul;42(7):1234-1245. doi: 10.1016/j.clinthera.2020.04.013. Epub 2020 May 22.
5
CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies.
AIDS Res Hum Retroviruses. 2018 Nov;34(11):982-992. doi: 10.1089/AID.2018.0062. Epub 2018 Aug 15.
6
Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.
HIV Med. 2017 Sep;18(8):537-545. doi: 10.1111/hiv.12488. Epub 2017 Feb 1.
7
Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.
Br J Clin Pharmacol. 2015 Jul;80(1):146-56. doi: 10.1111/bcp.12590. Epub 2015 May 28.
8
CYP2B6 Haplotype Predicts Efavirenz Plasma Concentration in Black South African HIV-1-Infected Children: A Longitudinal Pediatric Pharmacogenomic Study.
OMICS. 2017 Aug;21(8):465-473. doi: 10.1089/omi.2017.0078.
9
Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti.
J Antimicrob Chemother. 2014 Aug;69(8):2187-90. doi: 10.1093/jac/dku088. Epub 2014 Apr 2.
10
Impact of Efavirenz Metabolism on Loss to Care in Older HIV+ Africans.
Eur J Drug Metab Pharmacokinet. 2019 Apr;44(2):179-187. doi: 10.1007/s13318-018-0507-5.
引用本文的文献
1
Population Pharmacokinetic-Pharmacogenetic (PopPK-PGx) Model of Efavirenz in HIV-1-Infected Patients.
Cureus. 2025 Jul 22;17(7):e88533. doi: 10.7759/cureus.88533. eCollection 2025 Jul.
2
Next-Generation Approaches in Sports Medicine: The Role of Genetics, Omics, and Digital Health in Optimizing Athlete Performance and Longevity-A Narrative Review.
Life (Basel). 2025 Jun 27;15(7):1023. doi: 10.3390/life15071023.
3
The Influence of CYP2B6, GSTP1, and SLCO1B1 Star Allele-Predicted Phenotypes and CBR1 Genetic Variants on Effectiveness Outcomes in Patients With Hepatocellular Carcinoma Receiving Doxorubicin via Transarterial Chemoembolization.
Pharmacol Res Perspect. 2025 Jun;13(3):e70114. doi: 10.1002/prp2.70114.
4
Opportunities and Challenges of Population Pharmacogenomics.
Ann Hum Genet. 2025 Sep;89(5):384-397. doi: 10.1111/ahg.12596. Epub 2025 Apr 2.
5
CYP2B6 genetic variation in cyclophosphamide metabolism and hemorrhagic cystitis in Fanconi anemia patients undergoing allogeneic hematopoietic cell transplantation: A descriptive genetic association study.
Medicine (Baltimore). 2025 Mar 21;104(12):e41937. doi: 10.1097/MD.0000000000041937.
6
Pharmacogenomic profiling of variants affecting efficacy and toxicity of anti-infective medicines in a south Asian population from Sri Lanka.
BMC Infect Dis. 2025 Feb 1;25(1):153. doi: 10.1186/s12879-025-10538-w.
7
Pharmacogenetics of the Treatment of Neglected Diseases.
Genes (Basel). 2025 Jan 5;16(1):54. doi: 10.3390/genes16010054.
8
Pharmacogenomic profiling of the South Korean population: Insights and implications for personalized medicine.
Front Pharmacol. 2024 Dec 3;15:1476765. doi: 10.3389/fphar.2024.1476765. eCollection 2024.
9
Decoding Pharmacogenomic Test Interpretation and Application to Patient Care.
J Am Coll Clin Pharm. 2024 Jun;7(6):581-588. doi: 10.1002/jac5.1958. Epub 2024 May 8.
10
Sub- and supratherapeutic efavirenz plasma concentrations with risk for HIV therapy failure are mainly genetically explained in Ugandan children: The prospective GENEFA cohort study.
Br J Clin Pharmacol. 2025 Feb;91(2):464-478. doi: 10.1111/bcp.16272. Epub 2024 Oct 8.
本文引用的文献
1
Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants.
J Infect Dis. 2017 Sep 1;216(5):554-564. doi: 10.1093/infdis/jix248.
2
CYP2B6 genotypes and early efavirenz-based HIV treatment outcomes in Botswana.
AIDS. 2017 Sep 24;31(15):2107-2113. doi: 10.1097/QAD.0000000000001593.
3
CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection.
AIDS. 2017 May 15;31(8):1129-1136. doi: 10.1097/QAD.0000000000001463.
4
Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition.
Antimicrob Agents Chemother. 2016 Dec 27;61(1). doi: 10.1128/AAC.01813-16. Print 2017 Jan.
5
Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race.
Pharmacogenet Genomics. 2016 Oct;26(10):473-80. doi: 10.1097/FPC.0000000000000238.
6
Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation in CYP2B6*6*6 Allele Carriers.
J Cardiovasc Electrophysiol. 2016 Oct;27(10):1206-1213. doi: 10.1111/jce.13032. Epub 2016 Jul 25.
7
Developmental Expression of CYP2B6: A Comprehensive Analysis of mRNA Expression, Protein Content and Bupropion Hydroxylase Activity and the Impact of Genetic Variation.
Drug Metab Dispos. 2016 Jul;44(7):948-58. doi: 10.1124/dmd.115.067546. Epub 2015 Nov 25.
8
Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis.
EBioMedicine. 2015 May 12;2(7):706-12. doi: 10.1016/j.ebiom.2015.05.012. eCollection 2015 Jul.
9
PharmGKB summary: Efavirenz pathway, pharmacokinetics.
Pharmacogenet Genomics. 2015 Jul;25(7):363-76. doi: 10.1097/FPC.0000000000000145.
10
Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection.
J Infect Dis. 2015 Jan 15;211(2):197-205. doi: 10.1093/infdis/jiu429. Epub 2014 Jul 31.
Zotero 插件